170 related articles for article (PubMed ID: 33307889)
1. Evolutionary journey of programmatic services and treatment outcomes among drug resistant tuberculosis (DR-TB) patients under National TB Elimination Programme in India (2005-2020).
Sachdeva KS; Parmar M; Patel Y; Gupta R; Rathod S; Chauhan S; Anand S; Ramachandran R
Expert Rev Respir Med; 2021 Jul; 15(7):885-898. PubMed ID: 33307889
[No Abstract] [Full Text] [Related]
2. Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement.
Parmar MM; Sachdeva KS; Dewan PK; Rade K; Nair SA; Pant R; Khaparde SD
PLoS One; 2018; 13(4):e0193903. PubMed ID: 29641576
[TBL] [Abstract][Full Text] [Related]
3. Genomic revolution: Transforming tuberculosis diagnosis and treatment with the use of Whole Genome Sequencing - A consensus statement.
Arora VK; Jindal SK; Katiyar SK; Behra D; Talwar D; Sarin R; Dhar R; Mehta P; Bhargava S; Singhal P; Joshi S; Tiwaskar M; Nikam C; Chatterjee A; Vora A
Indian J Tuberc; 2023 Oct; 70(4):383-389. PubMed ID: 37968042
[TBL] [Abstract][Full Text] [Related]
4. Current and developing therapies for the treatment of multi drug resistant tuberculosis (MDR-TB) in India.
Muniyandi M; Ramachandran R
Expert Opin Pharmacother; 2017 Sep; 18(13):1301-1309. PubMed ID: 28786691
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and patterns of drug resistant pulmonary tuberculosis in India-A systematic review and meta-analysis.
Lohiya A; Suliankatchi Abdulkader R; Rath RS; Jacob O; Chinnakali P; Goel AD; Agrawal S
J Glob Antimicrob Resist; 2020 Sep; 22():308-316. PubMed ID: 32247079
[TBL] [Abstract][Full Text] [Related]
6. Isoniazid mono-resistant tuberculosis: Time to take it seriously.
Garg K; Saini V; Dhillon R; Agarwal P
Indian J Tuberc; 2019 Apr; 66(2):247-252. PubMed ID: 31151492
[TBL] [Abstract][Full Text] [Related]
7. The Potential Impact of Up-Front Drug Sensitivity Testing on India's Epidemic of Multi-Drug Resistant Tuberculosis.
Sachdeva KS; Raizada N; Gupta RS; Nair SA; Denkinger C; Paramasivan CN; Kulsange S; Thakur R; Dewan P; Boehme C; Arinaminpathy N
PLoS One; 2015; 10(7):e0131438. PubMed ID: 26132584
[TBL] [Abstract][Full Text] [Related]
8. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
[TBL] [Abstract][Full Text] [Related]
9. Status of universal drug-susceptibility testing among sputum smear-positive tuberculosis patients diagnosed at a tertiary care centre.
Debolina P; Palanivel C; Manju R; Tanveer R
Indian J Med Res; 2023; 157(2&3):216-219. PubMed ID: 37202940
[TBL] [Abstract][Full Text] [Related]
10. Trends in rifampicin and isoniazid resistance in patients with presumptive TB.
Palani N; Premkumar M; Vaishnavee V; Dinesh V; Thiruvengadam K; Lavanya J; Sridhar R; Frederick A; Sivaramakrishnan G; Mondal R; Padmapriyadarsini C; Shanmugam S
Int J Tuberc Lung Dis; 2022 May; 26(5):446-453. PubMed ID: 35505474
[No Abstract] [Full Text] [Related]
11. Treatment outcomes of children and adolescents receiving drug-resistant TB treatment in a routine TB programme, Mumbai, India.
Dhakulkar S; Das M; Sutar N; Oswal V; Shah D; Ravi S; Vengurlekar D; Chavan V; Rebello L; Meneguim AC; Iyer A; Mansoor H; Kalon S; Acharya S; Ferlazzo G; Isaakidis P; Thakur HP
PLoS One; 2021; 16(2):e0246639. PubMed ID: 33600431
[TBL] [Abstract][Full Text] [Related]
12. Impact of UDST: A step forward to end TB.
Kumar Sharma A; Vijay S; Mathur RB; Meena H
Indian J Tuberc; 2020 Apr; 67(2):213-215. PubMed ID: 32553314
[TBL] [Abstract][Full Text] [Related]
13. Multi-Drug Resistant and Extensively-Drug Resistant Tuberculosis.
Shah I; Poojari V; Meshram H
Indian J Pediatr; 2020 Oct; 87(10):833-839. PubMed ID: 32103425
[TBL] [Abstract][Full Text] [Related]
14. Alarming levels of drug-resistant tuberculosis in HIV-infected patients in metropolitan Mumbai, India.
Isaakidis P; Das M; Kumar AM; Peskett C; Khetarpal M; Bamne A; Adsul B; Manglani M; Sachdeva KS; Parmar M; Kanchar A; Rewari BB; Deshpande A; Rodrigues C; Shetty A; Rebello L; Saranchuk P
PLoS One; 2014; 9(10):e110461. PubMed ID: 25333696
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of multi drug resistant tuberculosis in people living with HIV in Western India.
Saldanha N; Runwal K; Ghanekar C; Gaikwad S; Sane S; Pujari S
BMC Infect Dis; 2019 May; 19(1):391. PubMed ID: 31068153
[TBL] [Abstract][Full Text] [Related]
16. Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects.
Yew WW
Kekkaku; 2011 Jan; 86(1):9-16. PubMed ID: 21401001
[TBL] [Abstract][Full Text] [Related]
17. Has introduction of rapid drug susceptibility testing at diagnosis impacted treatment outcomes among previously treated tuberculosis patients in Gujarat, India?
Dave P; Vadera B; Kumar AM; Chinnakali P; Modi B; Solanki R; Patel P; Patel P; Pujara K; Nimavat P; Shah A; Bharaswadkar S; Rade K; Parmar M; Nair SA
PLoS One; 2015; 10(4):e0121996. PubMed ID: 25874545
[TBL] [Abstract][Full Text] [Related]
18. Drug resistance and associated genetic mutations among patients with suspected MDR-TB in Uttar Pradesh, India.
Jain A; Singh PK; Chooramani G; Dixit P; Malhotra HS
Int J Tuberc Lung Dis; 2016 Jul; 20(7):870-5. PubMed ID: 27287637
[TBL] [Abstract][Full Text] [Related]
19. What will it take to eliminate drug-resistant tuberculosis?
Kendall EA; Sahu S; Pai M; Fox GJ; Varaine F; Cox H; Cegielski JP; Mabote L; Vassall A; Dowdy DW
Int J Tuberc Lung Dis; 2019 May; 23(5):535-546. PubMed ID: 31097060
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
